Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,466,544 papers from all fields of science
Search
Sign In
Create Free Account
20 ML atezolizumab 60 MG/ML Injection [Tecentriq]
Known as:
Tecentriq 1200 MG in 20 ML Injection
, atezolizumab 1200 mg in 20 mL INTRAVENOUS INJECTION, SOLUTION [TECENTRIQ]
, 20 ML Tecentriq 60 MG/ML Injection
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Acetic Acid
Histidine
Injection
Polysorbate 20
Expand
Broader (1)
atezolizumab Injection [Tecentriq]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
Connie Kang
,
Yahiya Y. Syed
Drugs
2020
Corpus ID: 214783542
Atezolizumab (Tecentriq ® ), an immune checkpoint inhibitor against programmed death ligand 1 (PD-L1), is the first immunotherapy…
Expand
2019
2019
Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triple-negative breast cancer (aTNBC)
L. McGahan
2019
Corpus ID: 149474080
In patients with triple negative breast cancer (TNBC), overexpression of programmed death ligand 1 (PD-L1) on tumour-infiltrating…
Expand
2018
2018
mCRPC: Praxiserfahrungen mit Abirateronacetat in der Erstlinie
D. Wedekind
Uro-News
2018
Corpus ID: 41041045
— Im Zentrum der Krebsimmuntherapie steht derzeit die Checkpointblockade. Dabei wurden zunächst die Checkpointmoleküle PD-1 und…
Expand
2018
2018
PD-L1-Inhibitor: eine neue Option im Kampf gegen Urothelkarzinome
D. Berger
Uro-News
2018
Corpus ID: 2303673
— Im Zentrum der Krebsimmuntherapie steht derzeit die Checkpointblockade. Dabei wurden zunächst die Checkpointmoleküle PD-1 und…
Expand
2017
2017
Atézolizumab (Tecentriq®) : activité, indication et modalités d’utilisation dans les carcinomes urothéliaux localement avancés ou métastatiques
A. Bernard.Tessier
,
C. Bonnet
,
Pernelle Lavaud
,
M. Gizzi
,
Y. Loriot
,
C. Massard
2017
Corpus ID: 196497545
Review
2017
Review
2017
[Atezolizumab (Tecentriq®): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma].
A. Bernard-Tessier
,
C. Bonnet
,
P. Lavaud
,
M. Gizzi
,
Y. Loriot
,
C. Massard
Bulletin du Cancer
2017
Corpus ID: 3606003
2017
2017
Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC)
L. McGahan
2017
Corpus ID: 80086835
Atezolizumab, a monoclonal antibody, is an immune checkpoint inhibitor. By inhibiting the programmed death ligand 1 (PD-L1…
Expand
2017
2017
PD-L1-Inhibition — beim Urothelkarzinom und bei Lungenkrebs eine neue Option
D. Berger
Im Focus Onkologie
2017
Corpus ID: 103689506
— Atezolizumab (Tecentriq®), ein PD-L1Antikörper, ist jetzt für das lokal fortgeschrittene oder metastasierte Urothelkarzinom…
Expand
2017
2017
CHMP recommends EU approval for Roche ’ s TECENTRIQ ® ( atezolizumab ) in a specific type of metastatic lung and two types of metastatic bladder cancer
F. Roche
2017
Corpus ID: 624996
CHMP recommends EU approval for Roche’s TECENTRIQ® (atezolizumab) in a specific type of metastatic lung and two types of…
Expand
Review
2016
Review
2016
Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma
L. McGahan
2016
Corpus ID: 78955443
Up-regulation of the programmed death ligand 1 (PD-L1) in patients with haematological malignancies and solid tumours increases…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE